Bispecific IgG are heterotetramers comprising 2 pairs of heavy and light chains. Co-expression of the 4 component chains in a single host cell typically yields the desired bispecific IgG plus up to 9 additional incorrect chain pairings. Several protein engineering strategies have been reported to facilitate the heterodimerization of antibody heavy chains or cognate pairing of antibody heavy and light chains. These technologies have been used to direct the efficient assembly of bispecific IgG in single host cells and minimize unwanted chain pairings. When purifying bispecific IgGs, the identification and quantification of low levels of closely related IgG contaminants are substantial analytical challenges. Here we have developed a robust high-throughput method for quantitative analysis of bispecific IgG preparations using novel online liquid chromatography in conjunction with an extended mass range Orbitrap-based high-resolution mass spectrometer. A mathematical method was developed to estimate the yields of the 2 isobaric species, namely the desired bispecific IgG and the light chain-scrambled IgG. The analytical methods described herein are anticipated to be broadly applicable to the development of bispecific IgG as drugs and potentially to other complex next-generation biotherapeutics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098441PMC
http://dx.doi.org/10.1080/19420862.2016.1232217DOI Listing

Publication Analysis

Top Keywords

bispecific igg
28
single host
12
igg
9
bispecific
8
host cells
8
high-resolution mass
8
heavy light
8
light chains
8
desired bispecific
8
chain pairings
8

Similar Publications

[Advances in structural design of T cell-dependent bispecific antibodies].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

October 2024

No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051, China. *Corresponding author, E-mail:

With the development of antibody engineering, a diverse range of structures for T cell-dependent bispecific antibodies targeting CD3 have been devised to meet the needs of various clinical therapies. T cell-dependent bispecific antibodies can be categorized into IgG-like and non-IgG-like formats based on the presence or absence of an Fc domain. The most common difficulty in manufacturing bispecific antibodies is the mispairing between light and heavy chains.

View Article and Find Full Text PDF

Bispecific antibodies (bsAbs) are emerging immune-therapeutics, and many formats exist that differ considerably in structure. However, little systematic data exist about how the spatial organization of their components influences activity, requiring innovative approaches combining empirical and quantitative frameworks. This study presents a modular DNA nanotechnology platform to generate numerous bsAbs with surrogate geometries that span the structural features of the BiTE, IgG-like, and IgG-conjugate platforms to screen for T-cell engagement.

View Article and Find Full Text PDF

General strategies for IgG-like bispecific antibody purification.

Biotechnol Prog

October 2024

Downstream Process Development (DSPD), WuXi Biologics, Shanghai, China.

Bispecific antibodies (bsAbs) can simultaneously bind two different antigens or epitopes. Their dual-targeting capability enables novel mechanisms of action, gaining therapeutic advantages over conventional monospecific mAbs. In recent years, the number of bsAbs grows rapidly and bsAbs under development are available in diverse formats.

View Article and Find Full Text PDF

Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation.

J Thromb Haemost

October 2024

Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Germany; Center for Rare Diseases Bonn (Zentrum für seltene Erkrankungen der Universität Bonn), University Clinic Bonn, Bonn, Germany. Electronic address:

Background: Acquired hemophilia A (AHA) is a rare and severe bleeding disorder characterized by autoantibodies inhibiting coagulation factor (F)VIII. Current treatment of AHA involves bypassing agents or FVIII replacement therapy, yet their efficacy is limited in cases of high inhibitor titers. Emicizumab, a humanized bispecific monoclonal antibody, has shown promising hemostatic effectiveness in persons with congenital hemophilia A (HA) and AHA, but a minority of patients developed anti-drug antibodies (ADAs), compromising its efficacy.

View Article and Find Full Text PDF
Article Synopsis
  • * A total of 66 eyes from 62 patients were evaluated, showing improvements in best corrected visual acuity and reductions in central macular thickness and retinal fluid after treatment with Faricimab.
  • * The results indicate that three loading doses of Faricimab are both effective, leading to significant visual and anatomical improvements, and safe, with only one minor adverse event reported.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!